Replies to post #162481 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

"What exactly are you suggesting NWBO should have done? Concluded the trial based on data showing that they had not yet met the minimum number of OS events?" -- IkeEsq

They have reached the minimum number events. That had to have occurred sometime last year, probably late summer. Due to LP's language and controlled environment at February 2018 ASM, it is clear to me she did not eliminate the fact that an efficacy analysis may have been performed around 233 OS last fall.

If successful, it would not require unblinding the trial until long tail data was in. This is how I read it. There was, imo, an efficacy analysis last fall on the primary and perhaps secondary endpoints, and now they are gathering further longterm data at the 2018 spring refresh to provide to regulators like NICE. IMO.

The noise here is to think of every slight iteration except the one above. It's to overstate it (overzealous longs), to understate it, to completely contest it (overzealous naysayers). Most probably want this to remain under wraps in the dusty archives of penny OTC until results and news are provided. OTC is OK, but penny stocks are, well penny stocks.

The only thing that really super-duper effectuates the full dilution regarding this stock in the forseeable future is if there is a buyout. Then all diluted shares will be counted as well. If this does not occur, then there are a huge number of closely held shares that could cause a share shortage. I would not be surprised to see Toucan separately file a form 4 or 13D or whatever for shares they may have received back as payment on loans they provided to Cognate.

I think this is all adding up to a very closely held company. If I'm wrong then I'm wrong.

I guess, to be honest, I've been kind of pulling for a buyout myself, because everything seems such a mess to us outsiders, but the reality is, if management are not the greedy monsters bears describe them as, then a buyout is probably least beneficial for shareholders if the trial is successful.

JMHO.